NYSE$PEN

Penumbra Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Reported a revenue increase of 25.5% and income from operations of $17.9 million compared to a loss in the previous year.

Penumbra, Inc. reported a strong second quarter with a 25.5% increase in revenue, reaching $261.5 million. The company's income from operations turned positive, reaching $17.9 million, compared to a loss in the same quarter last year. They are also increasing their revenue guidance for the year.

  • Total revenue increased to $261.5 million, a 25.5% increase compared to Q2 2022.
  • Vascular product revenue grew to $152.7 million, a 23.6% increase.
  • Neuro product revenue grew to $108.8 million, a 28.3% increase.
  • Income from operations was $17.9 million, compared to a loss of $0.1 million in Q2 2022.

Headline financials

Total Revenue

$261M

Previous: $208M+25.5%
EPS (adj)

$0.43

Previous: $0.01+4200.0%
Gross Margin

63.8%

Previous: 64.3%-0.8%
Capital Expenditures

-$8.24M

Previous: -$9.39M+12.3%
Free Cash Flow

$10.7M

Previous: -$13.1M+182.0%
Net Income

$19M

Previous: -$3.69M+614.2%
Operating Income

$17.9M

Previous: -$139K+12969.8%
Gross Profit

$167M

Previous: $134M+24.5%
Cash & Equivalents

$114M

Previous: $58.2M+96.0%
Total Assets

$1.43B

Previous: $1.33B+7.9%
Stock-Based Comp

$12.8M

Previous: $8.79M+45.9%

Revenue & EPS history

Penumbra · Revenue · Quarterly

$261M

Q2 2023+25.5%vs Q2 2022
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

Penumbra · $271M total across 2 segments · Q3 2023

  • Thrombectomy
    $179M
  • Embolization and Access
    $91.9M

Forward guidance

The Company is increasing its guidance for 2023 total revenue to be in the range of $1.05 billion to $1.07 billion, which represents 24% to 26% growth over 2022 revenue of $847.1 million. We continue to expect growth in our global vascular business to be slightly above this range and growth in our global neuro business to be below this range for the full year 2023.

Tailwinds

  • Total revenue is expected to be in the range of $1.05 billion to $1.07 billion.
  • Revenue growth of 24% to 26% is expected over 2022 revenue.
  • Global vascular business growth is expected to be slightly above the total revenue growth range.
  • Gross margin may be positively impacted with favorable product mix.
  • Gross margin may be positively impacted by leveraging our fixed costs on higher volume of new product sales during the year.

Headwinds

  • Global neuro business growth is expected to be below the total revenue growth range.
  • Gross margin is impacted by product mix.
  • Gross margin is impacted by regional mix.
  • Gross margin is impacted by start-up costs associated with new product launches.
  • Gross margin is impacted by macroeconomic factors such as inflation headwinds.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

+2.0%

Avg return

Earnings day

+1.3%

Avg return

5 days after

+1.9%

Avg return

30 days after

57%

28 / 49 earnings

Positive

+23.4%

Q4 2014

Best reaction

-15.8%

Q2 2018

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.1%-0.7%-1.1%
Q4 2025+0.9%+0.4%-1.1%
Q3 2025+17.1%+24.0%+33.3%
Q1 2025+7.0%+6.5%-3.7%
Q4 2024+12.0%+6.1%+3.4%
Q3 2024+9.2%+9.5%+16.5%
Q2 2024-6.3%-1.6%+13.5%
Q1 2024-4.0%+0.3%-7.2%
Q4 2023-7.7%-10.1%-13.0%
Q3 2023+2.0%+1.3%+17.4%
Q2 2023-11.2%-16.8%-12.8%
Q1 2023+5.5%+8.6%+10.1%
Q4 2022+2.3%-0.5%+5.1%
Q3 2022+3.0%+12.0%+34.0%
Q2 2022+13.7%+8.7%+12.5%
Q1 2022-3.6%-15.3%-17.6%
Q4 2021-3.4%+5.6%-2.6%
Q3 2021+3.0%-1.8%-14.8%
Q2 2021-2.1%-2.4%+3.0%
Q1 2021-8.3%-8.9%-13.9%
Q4 2020+3.2%+1.6%-3.4%
Q3 2020+10.6%+3.9%-5.1%
Q2 2020+2.5%+5.5%-3.5%
Q1 2020+1.4%+2.4%+1.4%
Q4 2019-6.8%-10.0%-13.7%
Q3 2019-0.8%+0.6%+1.0%
Q2 2019-6.9%-6.5%-15.1%
Q1 2019+3.0%-0.2%+17.8%
Q4 2018-11.2%-5.7%-1.1%
Q3 2018+7.2%+9.0%+1.1%
Q2 2018-15.8%-16.0%-3.8%
Q1 2018+9.5%+10.2%+15.7%
Q4 2017+3.9%+8.4%+11.0%
Q3 2017+9.3%+2.3%-3.3%
Q2 2017+5.8%+4.1%+4.4%
Q1 2017+4.3%-2.3%+1.0%
Q4 2016+3.8%+5.2%+7.8%
Q3 2016-2.5%+2.4%-4.2%
Q2 2016+10.9%+10.8%+6.6%
Q1 2016-1.7%
Q1 2015-1.7%
Q2 2014-6.3%
Q4 2015-6.3%
Q4 2013-6.3%
Q2 2015-6.3%
Q1 2014-6.3%
Q3 2014+23.4%
Q3 2015+23.4%
Q4 2014+23.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro